美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Avalyn Pharma

28.11

+1.485.56%

盤後：28.110.00000.00%16:10 EDT

成交量：12.61萬

成交額：350.16萬

市值：11.75億

市盈率：-13.79

高：28.61

開：26.75

低：26.00

收：26.63

52周最高：32.23

52周最低：25.05

股本：4,181.20萬

流通股本：1,666.67萬

量比：0.41

換手率：0.76%

股息：- -

股息率：- -

每股收益(TTM):-2.0380

淨資產收益率：-68.34%

總資產收益率：-41.74%

市淨率：-4.92

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%

肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克

Avalyn Pharma任命行業領袖Adam Golden與Frank Salisbury，強化領導團隊以支持長期增長

肺纖維化生物技術公司Avalyn Pharma(AVLN.US)IPO定價16至18美元擬募資2.01億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AVLN"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":28.11,"timestamp":1779220800000,"preClose":26.63,"halted":0,"volume":126141,"hourTrading":{"tag":"盘后","latestPrice":28.11,"preClose":28.11,"latestTime":"16:10 EDT","volume":9,"amount":252.99,"timestamp":1779221404333,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0555764175741645,"floatShares":16666700,"shares":41812047,"eps":-2.038,"marketStatus":"未開盤","change":1.48,"latestTime":"05-19 16:00:00 EDT","open":26.75,"high":28.61,"low":26,"amount":3501633.1842,"amplitude":0.09801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.038,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1779264000000},"marketStatusCode":0,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":26.63,"postHourTrading":{"tag":"盘后","latestPrice":28.11,"preClose":28.11,"latestTime":"16:10 EDT","volume":9,"amount":252.99,"timestamp":1779221404333,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.413718},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":0,"volumeRatio":0.413718,"shares":41812047,"dividePrice":0,"high":28.61,"amplitude":0.09801,"preClose":26.63,"low":26,"week52Low":25.05,"pbRate":"-4.92","week52High":32.225,"institutionHeld":0,"latestPrice":28.11,"eps":-2.038,"divideRate":0,"volume":126141,"delay":0,"ttmEps":-2.038,"open":26.75,"prevYearClose":18,"prevWeekClose":29.84,"prevMonthClose":29.49,"prevQuarterClose":18,"fiveDayClose":29.9,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-05-18","current":-13.792934,"percent":0.25,"low":-15.129165,"twenty":-14.66101,"median":-14.471589,"eighty":-13.431244,"high":-8.833116,"avg":-13.837039,"sd":1.567162,"marketCap":1247671482},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-18","current":-14.643344,"twenty":-14.66101,"median":-14.471589,"eighty":-13.431244,"marketCap":1247671482}],"updateTime":1779258009353},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1197256686","title":"異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256686","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197256686?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 01:26","pubTimestamp":1777570002,"startTime":"0","endTime":"0","summary":"Avalyn Pharma今日盘中大涨44.44%，引起了市场的广泛关注。消息面上，Avalyn Pharma是一家专注于开发治疗罕见呼吸系统疾病吸入式药物的生物技术公司，其于今日正式在纳斯达克全球精选市场挂牌交易。这两款药物分别为吡非尼酮和尼达尼布的吸入制剂，针对特发性肺纤维化等疾病，旨在提升疗效并减少副作用。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507639","title":"肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507639?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 15:07","pubTimestamp":1777532834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家处于二期临床试验阶段的生物技术公司，专注于开发治疗罕见呼吸系统疾病的吸入式药物。Avalyn的股票预计于4月30日(周四)正式在纳斯达克全球精选市场挂牌交易。作为临床阶段的生物技术企业，Avalyn Pharma致力于研发针对罕见呼吸系统疾病的吸入式抗纤维化疗法。其核心候选药物AP01和AP02分别为吡非尼酮和尼达尼布的吸入制剂，旨在将已获批的抗纤维化药物直接递送至肺部，提升局部药物暴露量并减少全身性副作用。","market":"fut","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437125.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVIW.SI","SQQQ","TQQQ","ONEQ","GPIQ","QLD","FTEC","TQQY","AVLN","MNQmain","QQQM","QYLG","QQQA","BK4007","QQQJ","BK1147","JEPQ","PSQ","QQQ","QID","QDTE","QQQE","QQQY","IYW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154944245","title":"Avalyn Pharma任命行業領袖Adam Golden與Frank Salisbury，強化領導團隊以支持長期增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1154944245","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154944245?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 20:28","pubTimestamp":1777292892,"startTime":"0","endTime":"0","summary":"生物制药公司Avalyn Pharma宣布两项关键高层任命，旨在加强其领导团队实力，为公司长期发展提供战略支持。公司正式任命Adam Golden和Frank Salisbury担任重要领导职务，两位行业资深人士的加入将助力Avalyn推进其创新疗法研发管线。此次人事变动彰显了Avalyn Pharma在呼吸疾病治疗领域持续扩张的决心。通过对领导团队的战略性补强，Avalyn进一步巩固了其在新药研发领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629818634","title":"肺纖維化生物技術公司Avalyn Pharma(AVLN.US)IPO定價16至18美元 擬募資2.01億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629818634","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629818634?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 15:07","pubTimestamp":1777014466,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家专注于开发用于治疗罕见呼吸系统疾病的吸入式药物的二期生物技术公司，于周四公布了其首次公开募股条款。作为一家临床阶段的生物技术公司，Avalyn Pharma致力于开发用于治疗罕见呼吸系统疾病的吸入式抗纤维化疗法。自 2011 年成立以来，Avalyn 已累计获得超过 3.8 亿美元的私募股权投资。Avalyn Pharma成立于2011年，计划在纳斯达克上市，股票代码为AVLN。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UUP","AVLN","IPOS","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AVLN\",params:#limit:6,delay:false,,,undefined,":[]}}